$0.17
+1.29%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.17
From 52W high−93.83%
Volume2.93M
Market cap$12.39M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.17
From 52W high
−93.83%
Volume
2.93M
Market cap
$12.39M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
33.1
MomentumView details →
1D Return
+1.29%
YTD Return
−88.89%
SummaryUpdated Jun 1, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) is a clinical-stage biotechnology company that went public in November 2024. Founded as a biotech venture focused on developing innovative cancer treatments, the company specializes in advancing non-invasive therapeutic solutions for skin cancer. As a recently public entity, Medicus represents an early-stage biotech firm transitioning from private development to public markets while pursuing clinical trials for its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Medicus Pharma Ltd. issued 8,529,412 restricted common shares to certain officers and employees at $0.1705 per share, worth about $1.45 million, in lieu of cash bonuses under a private placement exempt from registration.9d agoMedicus Pharma published abridged final Phase 2 clinical study report results for its SkinJect D-MNA patch, identifying the 200 µg dose as the lead development dose.10d agoMedicus Pharma raised about $40 million through equity and debt financing during the first half of 2026.38d ago